Battistella Maxime, Beylot-Barry Marie, Bachelez Hervé, Rivet Jacqueline, Vergier Béatrice, Bagot Martine
Department of Pathology, Assistance Publique-Hôpitaux de Paris, Hôpital St Louis, Paris, France.
Arch Dermatol. 2012 Jul;148(7):832-9. doi: 10.1001/archdermatol.2011.3269.
Peripheral nodal follicular T-cell lymphomas expressing follicular helper T-cell (T(FH)) markers have recently been identified. Such lymphomas are characterized by a nodal neoplastic T-cell proliferation accompanied by numerous reactive B cells and demonstrate some overlap with nodal angioimmunoblastic T-cell lymphoma (AITL). We identified 5 cases of cutaneous T-cell lymphoma with a peculiar pathologic aspect and expression of T(FH) markers.
The mean age of the patients was 61 years (range, 33-78 years). Four patients had multiple papules, plaques, and nodules predominating on the trunk and the head. One had a nodular plaque on the face. Lesional T-cell clonality was found in all 5 patients, and blood T-cell clonality in 4 of the 5. Nodal involvement was never found. Patients had no systemic symptoms and no biological signs of AITL. In 3 cases, findings from skin biopsy specimens were initially misdiagnosed as primary cutaneous follicle B-cell lymphoma due to major B-cell infiltrate and CD10 positivity. Rituximab-containing therapies were ineffective in these cases, and biopsy specimens after treatment with rituximab showed medium- to large-sized atypical T-cell skin infiltrate expressing T(FH) markers (CD10, Bcl-6, PD-1, CXCL13, and ICOS). The final diagnosis proposed for all patients was cutaneous T(FH) lymphoma. The patient with localized disease was successfully treated with radiotherapy. Patients with diffuse disease showed marked resistance to treatments, with only 1 case of complete remission after allogeneic hematopoietic stem cell transplantation followed by bortezomib and donor-lymphocyte infusion. Bexarotene, methotrexate, thalidomide, interferon alfa, gemcitabine, liposomal doxorubicin, or multiagent chemotherapy with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) were either ineffective or induced transitory partial remission.
We describe an original clinicopathologic series of primary cutaneous lymphomas with T(FH) phenotype, suggesting the existence of a new entity among cutaneous T-cell lymphomas. Relations of these lymphomas with the provisional entity of primary cutaneous small to medium CD4 pleomorphic T-cell lymphoma need to be further addressed.
最近发现了表达滤泡辅助性T细胞(T(FH))标志物的外周淋巴结滤泡性T细胞淋巴瘤。此类淋巴瘤的特征为淋巴结肿瘤性T细胞增殖并伴有大量反应性B细胞,且与淋巴结血管免疫母细胞性T细胞淋巴瘤(AITL)存在一些重叠。我们鉴定出5例具有特殊病理表现并表达T(FH)标志物的皮肤T细胞淋巴瘤。
患者的平均年龄为61岁(范围33 - 78岁)。4例患者有多个丘疹、斑块和结节,主要分布于躯干和头部。1例患者面部有一个结节性斑块。所有5例患者均发现病变T细胞克隆性,5例中有4例血液T细胞存在克隆性。未发现有淋巴结受累情况。患者无全身症状,也无AITL的生物学迹象。3例患者的皮肤活检标本最初因大量B细胞浸润和CD10阳性而被误诊为原发性皮肤滤泡性B细胞淋巴瘤。含利妥昔单抗的治疗方法在这些病例中无效,利妥昔单抗治疗后的活检标本显示有表达T(FH)标志物(CD10、Bcl-6、PD-1、CXCL13和ICOS)的中至大型非典型T细胞皮肤浸润。所有患者最终诊断为皮肤T(FH)淋巴瘤。局限性疾病患者通过放疗成功治愈。弥漫性疾病患者对治疗表现出明显耐药,仅1例在异基因造血干细胞移植后联合硼替佐米和供体淋巴细胞输注后完全缓解。贝沙罗汀、甲氨蝶呤、沙利度胺、干扰素α、吉西他滨、脂质体阿霉素或CHOP(环磷酰胺、阿霉素、长春新碱和泼尼松)多药化疗要么无效,要么仅诱导短暂部分缓解。
我们描述了一组具有T(FH)表型的原发性皮肤淋巴瘤的原始临床病理系列,提示在皮肤T细胞淋巴瘤中存在一种新的实体。这些淋巴瘤与原发性皮肤中小CD4多形性T细胞淋巴瘤这一暂定实体之间的关系有待进一步探讨。